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1. Introduction 
Three major types of pyruvate kinase have been 
identified in mammalian tissues by electrophoretic 
[ 1,2] and immunological techniques [3]. Recently, 
Carbonell et al, [4] have achieved by kinetic studies 
on pyruvate kinases of rat and human tissues, the 
identification of three classes* of isozymes with 
qualitative differences in regulatory properties: the 
well known classes L (liver) and M (muscle), and a 
regulable new one which was designated as class A 
because it was first observed in adipose tissue [5,6]. 
This class A appears to be the same that the Ma -PK 
[3], PK-III [7] and PK-K [8] identified in other 
laboratories. It is the most widely extended class of 
pyruvate kinase in mammalian tissues including 
different tumoral cells [3,9,10]. 
The occurrence of interconvertible forms of 
pyruvate kinase has been previously reported. Pogson 
[S] found two interconvertible forms in pyruvate kinase 
from rat adipose tissue, and recently Walker and Potter 
[7] in pyruvate kinase from cultured hepatic cells. 
* This grouping of the isozymes in classes does not interfere 
with the recommendations of the IUPAC-IUB Commission 
on Biochemical Nomenclature [ 11) for the designation of 
individual isozymes. 
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We report here the kinetic characterization of the 
pyruvate kinase from Ehrlich ascites tumour cells as 
class A and evidence of two interconvertible forms 
of the enzyme with different regulatory properties. 
The form present in fresh extracts depends on the 
metabolic conditions of the cells prior to the homo- 
genization process. 
2. Materials and methods 
2.1. Biological material 
A hypertriploid strain of Ehrlich ascites carcinoma 
cells was grown in 2-month-old Swiss mice, and 
harvested about the seventh day after inoculation. 
The cells were withdrawn from the sacrificed animal, 
washed in an isotonic solution (140 mM NaCl and 5 
mM Tris-HCl pH 7.4), and centrifuged at low speed 
at 2-4”C. 
2.2. Preparation of extracts 
Washed cells were suspended in 10 mM Tris-HCl 
pH 7.4 and 0.5 mM dithioerythritol, placed in a 
propilene centrifuge tube and frozen and thawed 
twice in liquid nitrogen. The resulting homogenate 
was centrifuged at 30 000 g for 15 min at 2-4’C. 
Samples of the supernatant were used for kinetic 
studies, generally within 1 or 2 hr after its prepara- 
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tion and kept on ice from this moment until it was 
added to the assay mixture. 
2.3. Enzyme assay 
Pyruvate kinase was assayed by the method of 
Biicher and Pfleiderer [ 121 with a Gilford model 
2.400 spectrophotometer at 25°C. The final vol of 
the reaction mixture was 1 ml containing, unless 
indicated otherwise, 50 mM Tris-HCl pH 7.4,100 mM 
KCl, 5 mM MgClz , 0.15 mM NADH, 2 mM MgADP, 
2.5 mM phosphoenolpyruvate and 1 unit lactate 
dehydrogenase. Protein concentration was estimated 
by the method of Lowry et al. [ 131. 
Phosphoenolpyruvate (monosodium salt), fructose 
I ,6-bisphosphate (trisodium salt), nucleotides and 
auxiliary enzymes were from Boehringer. Amino 
acids were of the L-series, unless indicated otherwise, 
and obtained from Mann and Sigma. 
2.4. Preparation of starved cells 
Starved cells were prepared by incubating washed 
cells 4-6 hr in a phosphate saline solution in a shaking 
bath at 3O”C, with aeration. The phosphate saline 
solution contained: 144 mM NaCl, 17 mM Nas HP04 
and 3 mM NaH2P04, at final pH 7.4. The percentage 
of viable cells was controlled at the beginning and at 
the end of the incubation, by Tripan Blue staining 
[ 141. Initially the amount of stained cells was of 
2-3 per cent, and it did not increase after the starva- 
tion period. 
In two experiments the glycolytic flux, as indicated 
by the lactate production, of the tumour cells was 
measured by continuous recording of pH changes as 
described previously [ 151. In recently harvested cells 
the endogenous glycolysis was high, but in starved 
cells no lactate production was detected. However, 
after glucose addition the lactate production became 
normal. 
3. Results 
3.1. Kinetic characterization 
We have characterized the pyruvate kinase from 
extracts of recently harvested Ehrlich ascites tumour 
cells as class A, by the criteria developed by Carbonell 
et al. [4], since as shown in table 1, it is strongly 
inhibited by phenylahtnine and alanine and essentially 
Table 1 
Regulatory properties of pyruvate kinase from extracts of 
recently harvested Ehrlich ascites tumour cells 
Effecters Activity inhibition 
(units/mg protein) (%I 
None 0.55 _ 
Alanine 0.2 64 
Alanine + Fru-P, 0.55 - 
Phenylalanine 0.08 86 
Phenylalanine + Fru-P, 0.53 4 
MgATP 0.53 4 
The assay mixture was as indicated in Materials and methods, 
with 0.25 mM phosphoenolpyruvate. The final concentration 
of alanine, phenylalanine and MgATP was 2 mM. Fructose 
1,6-bisphosphate (Fru-P,) was assayed at 0.02 mM. 
unaffected by 2 mM MgATP, in contrast with the 
marked inhibition produced by the same concentna- 
tion of MgATP on class L pyruvate kinase [ 3 ,I 61. 
3.2. &uvate kinase from recently harvested, non- 
starved, tumour cells 
Extracts from recently harvested ascites cells were 
prepared as indicated above, and immediately assayed 
for pyruvate kinase activity. In these conditions the 
substrate-velocity curve, in the absence of effecters, 
was hyperbolic with an apparent K,.,, for phospho- 
enolpyruvate of 0.065 mM, but in the presence of 2 
mM alanine or phenylalanine it displayed a sigmoidal 
shape with nB VdUeS of 1.4 and 2 ESpeCtiVdy. 
Fig. 1 shows the effect of alanine and phenylalanine 
at different concentrations on the pyruvate kinase 
activity. The apparent 10~ values (inhibitor concentra- 
tion producing half-maximal inhibition), for alanine 
and phenylalanine were 0.1 and 0.4 mM respectively. 
As shown in the insert of this figure, the enzyme 
displays homotropic cooperativity for the amino acid 
inhibitions, with n’ values calculated by the method 
of Jensen and Nester [ 171 of 1.3 for alanine and 1.5 
for phenylalanine . 
Fructose 1,6-bisphosphate did not activate the 
enzyme in the absence of inhibitory amino acids, but 
reversed the inhibition produced by alanine and 
phenylaIanine with an apparent K, of 0.003 mM 
(not shown). Similar results have been obtained by 
Sparmannet al. [18]. 
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[Amino acid] ,mM 
Fig.1. Effects of alanine and phenylalanine on the activity 
of pyruvate kinase from recently harvested tumour cells. 
(m) Alanine and (A) phenylalanine. Assay as indicated in 
Materials and methods, with 0.25 mM phosphoenolpyruvate. 
In the insert, plots by the method of Jensen and Nester [ 171. 
[Phosphoendpyruvate] ,mM. 
Fig.2. Activity of pyruvate kinase from aged extracts of recent- 
ly harvested tumour cells, at various concentrations of phospho- 
enolpyruvate. (0) Without preincubation; preincubated with 
0.02 mM fructose 1,6-bis-phosphate (0) or 1 mM ATP (V), at 
25°C for 20 min. Assay as indicated in Materials and methods. 
In the insert a double-reciprocal plot of the kinetics in the 
absence of preincubation. 
3.3. Effect of the extract ageing on the substrate- 
velocity curve for phosphoerwlpyruvate 
The outlined kinetic study, as indicated, was 
carried out in fresh extracts of recently harvested 
cells. However when extracts kept in ice or at room 
temperattire for hours or extracts from cells with 
delayed homogenization were used, the substrate- 
velocity curve for phosphoenolpyruvate displayed a 
biphasic shape (fig.2). By the Lineweaver Burk Plot 
two enzymatic activities became evident with different 
apparent affinities for this substrate, one of them 
with a K, of 0.06 mM and the other, showing smaller 
affinity, with a K, of 0.5 mM. The incubation of the 
extracts displaying this anomalous kinetics with 
0.02 mM fructose 1,6-bisphosphate led to a Michaelis- 
Menton type, with high affinity for the phosphoenol- 
pyruvate. In contrast, the incubation of the same ex- 
tract with 1 mM ATP resulted in a pyruvate kinase 
form with sigmoidal substrate-velocity curve for 
phosphoenolpyruvate, with a So, of 0.5 mM and a 
nH value of 1.4 (fig.2). 
The effecters used in the preincubation experiments 
of the extracts, fructose 1,6-bisphosphate and ATP, 
were diluted 200 times when the extract sample was 
added to the reaction mixture. At the resulting con- 
centrations, there was no apparent effect on the 
kinetics, as tested separately. 
3.4. Pyruvate kinase from starved tumour cells 
Pyruvate kinase from extracts of cells kept in 
starvation conditions (see Materials and methods) for 
4-6 hr, showed a sigmoidal substrate-velocity curve 
for phosphoenolpyruvate with an apparent So, of 0.5 
mM and a nR value of 1.4, similar to the kinetics dis- 
played by pyruvate kinase from aged extracts incubat- 
ed with ATP, as reported above. The addition of 5 mM 
glucose to the starved cells carrying pyruvate kinase 
with sigmoidal kinetics against phosphoenolpyruvate, 
converted, in vivo, within 5 min, the enzyme to the 
form with hyperbolic kinetics and higher affinity for 
this substrate. 
Fig.3 shows the effect of alanine and phenylalanine 
at various concentrations on the activity of pyruvate 
kinase from starved tumour cells. The IO*5 values of 
the amino acids for this form of the enzyme are 0.02 
mM for alanine and 0.05 mM for phenylalanine. The 
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[Amino acid] ,mM. 
Fig.3. Effects of alanine and phenylalanine on the activity of 
pyruvate kinase from extracts of starved cells. (m) Alanine 
and (A) phenylalanine. Assay as indicated in Materials and 
methods, with 0.25 mM phosphoenolpyruvate. In the insert, 
plots by the method of Jensen and Nester [ 171. 
enzyme shows also homotropic cooperativity for the 
amino acid inhibitions with n’ values of 1.4 and 1.3 
for alanine and phenylalanine respectively. Cysteine 
also inhibits the enzyme, but to a lesser extent. The 
IO, value for cysteine was 0.02 mM with 0.25 mM 
phosphoenolpyruvate. The corresponding D-amino 
acids were completely ineffective. 
4. Discussion 
We report here that pyruvate kinase from Ehrlich 
ascites tumour cells belongs to class A, according to 
its regulatory properties, bringing new evidence on 
the presence of two interconvertible forms in pyruvate 
kinase class A, as reported for this class of pyruvate 
kinase from other sources [5,7,18], and showing 
regulatory differences between these two inter- 
convertible forms. One of these forms, present in 
extracts from cells with high glycolytic flux, shows 
a Michaelis-Menton kinetics against phosphoenol- 
pyruvate with high affinity for this substrate. It is the 
physiologically active form of the enzyme, since at 
the phosphoenolpyruvate and fructose 1,6-bisphos- 
phate concentrations in glycolysing ascites cells [ 191 
there is no inhibition by alanine and phenylalanine. 
The second form, present in extracts from cells 
undergoing little or no glycolysis, displays sigmoidal 
kinetics against phosphoenolpyruvate with low affinity 
for this substrate, and high sensitivity to alanine and 
phenylalanine inhibition. It should be practically 
inactive at in vivo concentrations of substrates and 
effecters [ 191. 
Aged extracts or extracts from cells with delayed 
homogenization, showed a biphasic substrate-velocity 
curve fbr the phosphoenolpyruvate that seems to 
correspond to a mixture of the two interconvertible 
forms of the enzyme, asindicated by the incubation 
of these extracts with ATP and fructose 1,6-bisphos- 
phate. In vitro, fructose 1,6-bisphosphate shifts the 
equilibrium between the two interconvertible forms, 
to the hyperbolic one, and ATP to the sigmoidal form 
of the enzyme. 
In vivo, the conversion of the sigmoidal (physiolo- 
gically inactive) form, present in starved cells, to the 
hyperbolic (highly active) form of the enzyme, follow- 
ing glucose addition to the suspension of starved cells, 
could be mediated by the rising of the intracellular 
concentration of fructose 1,6-bisphosphate in the 
first minute after the glucose addition [20,2 I 1. 
The physiological significance of these two inter- 
convertible forms of pyruvate kinase could be related 
to the coordination of the overall functioning of the 
glycolytic pathway. Besides phosphofructokinase, 
pyruvate kinase seems to be a key enzyme in the 
regulation of the lower part of glycolysis [6,1 S] . The 
fructose 1,6_bisphosphate level should be the meta- 
bolic indicator of the activity of the higher part of this 
pathway. When the level of this indicator drops because 
of slow glycolysis, the pyruvate kinase should be con- 
verted to the inactive form, braking the glycolytic 
flux in the lower part of the pathway, buffering in 
this manner the changes in the levels of the intermediates 
between phosphofructokinase and pyruvate kinase. 
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